RespireRx to Start Phase 2A Clinical Trial for CX1739
RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) announced that it’s been notified that the US Food and Drug Administration (FDA) has removed the clinical hold on its Investigational New Drug application for CX1739. The company can now start clinical trials.
RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) announced that it’s been notified that the US Food and Drug Administration (FDA) has removed the clinical hold on its Investigational New Drug application for CX1739. The company can now start clinical trials.
As quoted in the press release:
The Company intends to begin a Phase 2A clinical trial by March 31, 2016 to confirm the ability of CX1739, the Company’s proprietary lead ampakine, to antagonize the respiratory depressant effects of fentanyl, a potent opioid, without altering its analgesic properties. This pharmacological property previously had been reported for CX717, a predecessor ampakine.
Dr. James S. Manuso, president and CEO of RespireRx, commented:
We are extremely pleased to announce the advancement of the clinical and regulatory development of CX1739 for opioid-induced respiratory depression, the first of several indications involving respiratory disorders. The FDA clearance of our Phase 2A clinical trial of CX1739 provides further validation of RespireRx’s worldwide leadership role in the research and development of next-generation ampakine medicines. The RespireRx management team is committed to further developing its ampakine portfolio of medicines for a variety of indications where central nervous system-mediated breathing disorders may play a significant role, as is the case in Central Sleep Apnea, Pompé Disease and spinal cord injury. We look forward to reporting on our progress in the months and years ahead.
Click here to read the full RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) press release.
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1805.19 | -1.68 | |
Silver | 20.21 | -0.05 | |
Copper | 3.67 | -0.04 | |
Palladium | 1931.50 | +9.50 | |
Platinum | 898.00 | +1.00 | |
Oil | 106.13 | +0.37 | |
Heating Oil | 3.86 | +0.03 | |
Natural Gas | 5.72 | +0.30 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.